OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina

NANot yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Stable AnginaCoronary Artery Disease
Interventions
DRUG

Short DAPT

Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.

DRUG

Standard DAPT

Patients with high bleeding risk will receive aspirin and clopidogrel for 6 months after PCI (unoptimization confirmed in OCT), followed by single antiplatelet therapy thereafter.

DRUG

Extended DAPT

Patients (with stet unoptimazation results in OCT imaging) receive aspirin and clopidogrel for 12 months after PCI.

DEVICE

OCT-guided PCI

All patients undergo percutaneous coronary intervention with mandatory intravascular imaging using optical coherence tomography to assess stent optimization (expansion, apposition, dissection).

Trial Locations (1)

148

Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Korea University Guro Hospital

OTHER

NCT07198529 - OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina | Biotech Hunter | Biotech Hunter